1. Scribner, Juniper A, Hicks, Stuart W, Sinkevicius, Kerstin W, Bonvini, Ezio, Loo, Deryk. . Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. In Molecular cancer therapeutics, 21, 1047-1059. doi:10.1158/1535-7163.MCT-21-0915. https://pubmed.ncbi.nlm.nih.gov/35511740/
2. Bazzone, Lindsey E, Zhu, Junji, King, Michael, Finberg, Robert W, Kurt-Jones, Evelyn A. 2024. ADAM9 promotes type I interferon-mediated innate immunity during encephalomyocarditis virus infection. In Nature communications, 15, 4153. doi:10.1038/s41467-024-48524-6. https://pubmed.ncbi.nlm.nih.gov/38755212/
3. Chou, Cheng-Wei, Huang, Yu-Kai, Kuo, Ting-Ting, Liu, Jing-Pei, Sher, Yuh-Pyng. 2020. An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases. In International journal of molecular sciences, 21, . doi:10.3390/ijms21207790. https://pubmed.ncbi.nlm.nih.gov/33096780/
4. Huang, Yu-Kai, Cheng, Wei-Chung, Kuo, Ting-Ting, Yeh, Chun-Chieh, Sher, Yuh-Pyng. 2024. Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy. In Nature cancer, 5, 400-419. doi:10.1038/s43018-023-00720-x. https://pubmed.ncbi.nlm.nih.gov/38267627/
5. Le, Trang Thi-Huynh, Hsieh, Chia-Ling, Lin, I-Hsuan, Chen, Kuan-Chou, Sung, Shian-Ying. 2022. The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer. In American journal of cancer research, 12, 176-197. doi:. https://pubmed.ncbi.nlm.nih.gov/35141012/
6. Oria, Victor O, Lopatta, Paul, Schilling, Oliver. 2018. The pleiotropic roles of ADAM9 in the biology of solid tumors. In Cellular and molecular life sciences : CMLS, 75, 2291-2301. doi:10.1007/s00018-018-2796-x. https://pubmed.ncbi.nlm.nih.gov/29550974/
7. Oria, Victor O, Lopatta, Paul, Schmitz, Tatjana, Bronsert, Peter, Schilling, Oliver. 2019. ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. In Molecular oncology, 13, 456-479. doi:10.1002/1878-0261.12426. https://pubmed.ncbi.nlm.nih.gov/30556643/
8. Haoyuan, M A, Yanshu, L I. . Structure, regulatory factors and cancer-related physiological effects of ADAM9. In Cell adhesion & migration, 14, 165-181. doi:10.1080/19336918.2020.1817251. https://pubmed.ncbi.nlm.nih.gov/32875951/
9. Breun, Maria, Schwerdtfeger, Alexandra, Martellotta, Donato Daniel, Löhr, Mario, Hagemann, Carsten. 2020. ADAM9: A novel player in vestibular schwannoma pathogenesis. In Oncology letters, 19, 1856-1864. doi:10.3892/ol.2020.11299. https://pubmed.ncbi.nlm.nih.gov/32194680/
10. Umeda, Masataka, Yoshida, Nobuya, Hisada, Ryo, Owen, Caroline A, Tsokos, George C. . ADAM9 enhances Th17 cell differentiation and autoimmunity by activating TGF-β1. In Proceedings of the National Academy of Sciences of the United States of America, 118, . doi:10.1073/pnas.2023230118. https://pubmed.ncbi.nlm.nih.gov/33911034/
智鼠故事 
